Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation

Liver Transplantation

Volumn 20, Issue 11, 2014, Pages 1402-1412

  Hynynen, Johanna ^a,b   Komulainen, Tuomas ^a,b   Tukiainen, Eija ^c   Nordin, Arno ^c   Arola, Johanna ^d   Kälviäinen, Reetta ^e,f   Jutila, Leena ^e   Röyttä, Matias ^g   Hinttala, Reetta ^a,b   Majamaa, Kari ^a,b   Mäkisalo, Heikki ^c   Uusimaa, Johanna ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMMONIA; AMYLASE; ANTIBIOTIC AGENT; BILIRUBIN; BLOOD CLOTTING FACTOR; CALCINEURIN INHIBITOR; CLOBAZAM; CLONAZEPAM; CORTISONE; CYCLOSPORIN; ENOXAPARIN; ETIRACETAM; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; LACTIC ACID; LAMOTRIGINE; LIVER ENZYME; MITOCHONDRIAL DNA; OXCARBAZEPINE; PARACETAMOL; PREGABALIN; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; DNA DIRECTED DNA POLYMERASE; POLG PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; ATAXIA; BALANCE DISORDER; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; BRAIN EDEMA; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; COPPER URINE LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DIZZINESS; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHASIA; ELECTROENCEPHALOGRAM; EPILEPTIC DISCHARGE; EPILEPTIC STATE; FATIGUE; FATTY LIVER; FEMALE; FEMUR HEAD NECROSIS; FEVER; FOCAL EPILEPSY; FOLLOW UP; FULMINANT HEPATIC FAILURE; GENE; GENE MUTATION; GENETIC PREDISPOSITION; HAND TREMOR; HEADACHE; HEART ARREST; HEMOLYTIC ANEMIA; HEPATIC ENCEPHALOPATHY; HIP OSTEOARTHRITIS; HIP PROSTHESIS; HORMONAL CONTRACEPTION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPOREFLEXIA; IMMUNOSUPPRESSIVE TREATMENT; INTRACTABLE EPILEPSY; JAUNDICE; LACTATE BLOOD LEVEL; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; LOWER EXTREMITY DEEP VEIN THROMBOSIS; MALE; MIGRAINE WITH AURA; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL RECESSIVE ATAXIA SYNDROME; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PANCREAS EXOCRINE INSUFFICIENCY; PANCREATITIS; PANIC; PNEUMONIA; POLG1 GENE; POLYNEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTOPERATIVE PERIOD; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEVERE HEPATIC IMPAIRMENT; SHIVERING; SLEEP DEPRIVATION; SLOWNESS; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; URINE LEVEL; VISUAL DISORDER; VOMITING; WILSON DISEASE; ADOLESCENT; CASE REPORT; CHEMICALLY INDUCED; DRUG EFFECTS; FATALITY; GENETICS; LIVER; LIVER FAILURE, ACUTE; METABOLISM; MUTATION; PATHOLOGY; TRANSPLANTATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; DNA, MITOCHONDRIAL; DNA-DIRECTED DNA POLYMERASE; FATAL OUTCOME; FEMALE; HUMANS; LIVER; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MUTATION; RETROSPECTIVE STUDIES; TRANSPLANTS; VALPROIC ACID; YOUNG ADULT;

EID: 84914666742     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23965     Document Type: Article

References (50)

1. Kaguni LS. DNA polymerase gamma, the mitochondrial replicase. Annu Rev Biochem 2004;73:293-320.
2. Chan SS, Copeland WC. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochim Biophys Acta 2009;1787:312-319.
3. Naviaux RK, Nyhan WL, Barshop BA, Poulton J, Markusic D, Karpinski NC, et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome. Ann Neurol 1999;45:54-58.
4. Simonati A, Filosto M, Savio C, Tomelleri G, Tonin P, Dalla Bernardina B, et al. Features of cell death in brain and liver, the target tissues of progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher disease). Acta Neuropathol 2003;106:57-65.
5. Nguyen KV, Sharief FS, Chan SS, Copeland WC, Naviaux RK. Molecular diagnosis of Alpers syndrome. J Hepatol 2006;45:108-116.
6. Gordon N. Alpers syndrome: progressive neuronal degeneration of children with liver disease. Dev Med Child Neurol 2006;48:1001-1003.
7. Lee WS, Sokol RJ. Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology 2007;45:1555-1565.
8. Uusimaa J, Hinttala R, Rantala H, Päivärinta M, Herva R, Röyttä M, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia 2008;49:1038-1045.
9. El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics 2013;10:186-198.
10. Milone M, Massie R. Polymerase gamma 1 mutations: clinical correlations. Neurologist 2010;16:84-91.
11. Bicknese AR, May W, Hickey WF, Dodson WE. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann Neurol 1992;32:767-775.
12. Delarue A, Paut O, Guys JM, Montfort MF, Lethel V, Roquelaure B, et al. Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr Transplant 2000;4:67-71.
13. Kayihan N, Nennesmo I, Ericzon BG, Nemeth A. Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage. Pediatr Transplant 2000;4:211-214.
14. McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). BMJ Case Rep 2009;2009:10.1136/bcr.12.2008.1303.
15. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010;19:140-146.
16. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010;52:1791-1796.
17. Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006;129:1685-1692.
18. Engelsen BA, Tzoulis C, Karlsen B, Lillebø A, Laegreid LM, Aasly J, et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008;131:818-828.
19. Uusimaa J, Gowda V, McShane A, Smith C, Evans J, Shrier A, et al. Prospective study of POLG mutations presenting in children with intractable epilepsy: prevalence and clinical features. Epilepsia 2013;54:1002-1011.
20. Spinazzola A, Invernizzi F, Carrara F, Lamantea E, Donati A, Dirocco M, et al. Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis 2009;32:143-158.
21. Thomson M, McKiernan P, Buckels J, Mayer D, Kelly D. Generalised mitochondrial cytopathy is an absolute contraindication to orthotopic liver transplant in childhood. J Pediatr Gastroenterol Nutr 1998;26:478-481.
22. Sokal EM, Sokol R, Cormier V, Lacaille F, McKiernan P, Van Spronsen FJ, et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999;158(suppl 2):S81-S84.
23. Dubern B, Broue P, Dubuisson C, Cormier-Daire V, Habes D, Chardot C, et al. Orthotopic liver transplantation for mitochondrial respiratory chain disorders: a study of 5 children. Transplantation 2001;71:633-637.
24. Guo W, Jiang L, Bhasin S, Khan SM, Swerdlow RH. DNA extraction procedures meaningfully influence qPCR-based mtDNA copy number determination. Mitochondrion 2009;9:261-265.
25. He L, Chinnery PF, Durham SE, Blakely EL, Wardell TM, Borthwick GM, et al. Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res 2002; 30:e68.
26. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
27. Rahman S, Poulton J. Diagnosis of mitochondrial DNA depletion syndromes. Arch Dis Child 2009;94:3-5.
28. Moilanen V, Mäkisalo H. Wilson's disease. Duodecim 2010;126:635-642.
29. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-742.
30. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26(suppl 2):43-53.
31. Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamäki M, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005;77:430-441.
32. Hakonen AH, Isohanni P, Rantamäki M, Kälviäinen R, Nordin A, Uusimaa J, et al. Mitochondrial recessive ataxia syndrome (MIRAS) and valproate toxicity. Duodecim 2010;126:1552-1559.
33. Chan SS, Longley MJ, Copeland WC. Modulation of the W748S mutation in DNA polymerase gamma by the E1143G polymorphism in mitochondrial disorders. Hum Mol Genet 2006;15:3473-3483.
34. Winterthun S, Ferrari G, He L, Taylor RW, Zeviani M, Turnbull DM, et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology 2005;64:1204-1208.
35. Brunetti-Pierri N, Selby K, O'Sullivan M, Hendson G, Truong C, Waters PJ, et al. Rapidly progressive neurological deterioration in a child with Alpers syndrome exhibiting a previously unremarkable brain MRI. Neuropediatrics 2008;39:179-183.
36. Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2008;29:E150-E172.
37. Isohanni P, Hakonen AH, Euro L, Paetau I, Linnankivi T, Liukkonen E, et al. POLG1 manifestations in childhood. Neurology 2011;76:811-815.
38. Luoma PT, Luo N, Loscher WN, Farr CL, Horvath R, Wanschitz J, et al. Functional defects due to space-rregion mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome. Hum Mol Genet 2005;14:1907-1920.
39. Taanman JW, Rahman S, Pagnamenta AT, Morris AA, Bitner-Glindzicz M, Wolf NI, et al. Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion. Hum Mutat 2009;30:248-254.
40. Ferrari G, Lamantea E, Donati A, Filosto M, Briem E, Carrara F, et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gamma A. Brain 2005;128:723-731.
41. Horvath R, Hudson G, Ferrari G, Futterer N, Ahola S, Lamantea E, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006;129:1674-1684.
42. Kurt B, Jaeken J, Van Hove J, Lagae L, Löfgren A, Everman DB, et al. A novel POLG gene mutation in 4 children with Alpers-like hepatocerebral syndromes. Arch Neurol 2010;67:239-244.
43. Helbling D, Buchaklian A, Wang J, Wong LJ, Dimmock D. Reduced mitochondrial DNA content and heterozygous nuclear gene mutations in patients with acute liver failure. J Pediatr Gastroenterol Nutr 2013;57:438-443.
44. Ishikura H, Matsuo N, Matsubara M, Ishihara T, Takeyama N, Tanaka T. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996;20:55-58.
45. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol 2009;47:101-111.
46. Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;56:1405-1409.
47. De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli DR Jr, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998;39:1216-1225.
48. Kelly DA. Liver transplantation: to do or not to do? Pediatr Transplant 2000;4:170-172.
49. Wolf NI, Rahman S, Schmitt B, Taanman JW, Duncan AJ, Harting I, et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009;50:1596-1607.
50. Mindikoglu AL, King D, Magder LS, Ozolek JA, Mazariegos GV, Shneider BL. Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States. J Pediatr 2011;158:802-807.